-
1
-
-
27144540666
-
Mortality and survival in breast and colorectal cancer
-
Boyle P and Ferlay J: Mortality and survival in breast and colorectal cancer. Nat Clin Pract Oncol 2: 424-425, 2005.
-
(2005)
Nat Clin Pract Oncol
, vol.2
, pp. 424-425
-
-
Boyle, P.1
Ferlay, J.2
-
2
-
-
4644320061
-
-
Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O, Levi F and Bismuth H: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240: 644-657; discussion 657-648, 2004.
-
Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O, Levi F and Bismuth H: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240: 644-657; discussion 657-648, 2004.
-
-
-
-
3
-
-
0034712536
-
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
-
Douillard Jy, Cunningham D, Roth Ad, Navarro M, James Rd, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000.
-
(2000)
Lancet
, vol.355
, pp. 1041-1047
-
-
Douillard, J.1
Cunningham, D.2
Roth, A.3
Navarro, M.4
James, R.5
Karasek, P.6
Jandik, P.7
Iveson, T.8
Carmichael, J.9
Alakl, M.10
Gruia, G.11
Awad, L.12
Rougier, P.13
-
4
-
-
1342290189
-
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
-
Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and De Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
-
(2004)
J Clin Oncol
, vol.22
, pp. 229-237
-
-
Tournigand, C.1
Andre, T.2
Achille, E.3
Lledo, G.4
Flesh, M.5
Mery-Mignard, D.6
Quinaux, E.7
Couteau, C.8
Buyse, M.9
Ganem, G.10
Landi, B.11
Colin, P.12
Louvet, C.13
De Gramont, A.14
-
5
-
-
34249000361
-
-
Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M and Masi G: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676, 2007.
-
Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M and Masi G: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676, 2007.
-
-
-
-
6
-
-
0037531121
-
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial
-
Rothenberg MI, Oza Am, Bigelow Rh, Berlin Jd, Marshall JI, Ramanathan Rk, Hart LI, Gupta S, Garay Ca, Burger Bg, Le Bail N and Haller Dg: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069, 2003.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2059-2069
-
-
Rothenberg, M.I.1
Oza, A.2
Bigelow, R.3
Berlin, J.4
Marshall, J.I.5
Ramanathan, R.6
Hart, L.I.7
Gupta, S.8
Garay, C.9
Burger, B.10
Le Bail, N.11
Haller, D.12
-
7
-
-
20644432867
-
Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
-
Hurwitz Hi, Fehrenbacher L, Hainsworth Jd, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny Wf and Kabbinavar F: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508, 2005.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3502-3508
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Hainsworth, J.3
Heim, W.4
Berlin, J.5
Holmgren, E.6
Hambleton, J.7
Novotny, W.8
Kabbinavar, F.9
-
8
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
-
Saltz Lb, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang Ts, Rivera F, Couture F, Sirzen F and Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019, 2008.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2013-2019
-
-
Saltz, L.1
Clarke, S.2
Diaz-Rubio, E.3
Scheithauer, W.4
Figer, A.5
Wong, R.6
Koski, S.7
Lichinitser, M.8
Yang, T.9
Rivera, F.10
Couture, F.11
Sirzen, F.12
Cassidy, J.13
-
9
-
-
34248173883
-
-
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB, 3rd: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544, 2007.
-
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB, 3rd: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544, 2007.
-
-
-
-
10
-
-
23844448040
-
Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates
-
Folprecht G, Grothey A, Alberts S, Raab H and Kohne C: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16: 1311-1319, 2005.
-
(2005)
Ann Oncol
, vol.16
, pp. 1311-1319
-
-
Folprecht, G.1
Grothey, A.2
Alberts, S.3
Raab, H.4
Kohne, C.5
-
11
-
-
33746485766
-
Epidermal growth factor receptor targeting in cancer
-
Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385, 2006.
-
(2006)
Semin Oncol
, vol.33
, pp. 369-385
-
-
Mendelsohn, J.1
Baselga, J.2
-
12
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
-
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.
-
(2004)
N Engl J Med
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
Khayat, D.4
Bleiberg, H.5
Santoro, A.6
Bets, D.7
Mueser, M.8
Harstrick, A.9
Verslype, C.10
Chau, I.11
Van Cutsem, E.12
-
13
-
-
0842278693
-
Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: Oxaliplatin pharmacokinetics and feasibility
-
Guthoff I, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H and Kornmann M: Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res 23: 5203-5208, 2003.
-
(2003)
Anticancer Res
, vol.23
, pp. 5203-5208
-
-
Guthoff, I.1
Lotspeich, E.2
Fester, C.3
Wallin, I.4
Schatz, M.5
Ehrsson, H.6
Kornmann, M.7
-
14
-
-
36148941301
-
Cetuximab for the treatment of colorectal cancer
-
Jonker D, O'Callaghan C, Karapetis Cs, Zalcberg J, Tu D, Au H, Berry S, Krahn M, Price T, Simes R, Tebbutt N, Van Hazel G, Wierzbicki R, Langer C and Moore M: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048, 2007.
-
(2007)
N Engl J Med
, vol.357
, pp. 2040-2048
-
-
Jonker, D.1
O'Callaghan, C.2
Karapetis, C.3
Zalcberg, J.4
Tu, D.5
Au, H.6
Berry, S.7
Krahn, M.8
Price, T.9
Simes, R.10
Tebbutt, N.11
Van Hazel, G.12
Wierzbicki, R.13
Langer, C.14
Moore, M.15
-
15
-
-
34447264101
-
Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
-
Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J and Kohne C: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. ASCO Meeting Abstracts 25: 4000, 2007.
-
(2007)
ASCO Meeting Abstracts
, vol.25
, pp. 4000
-
-
Van Cutsem, E.1
Nowacki, M.2
Lang, I.3
Cascinu, S.4
Shchepotin, I.5
Maurel, J.6
Rougier, P.7
Cunningham, D.8
Nippgen, J.9
Kohne, C.10
-
16
-
-
36348990562
-
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study
-
Bokemeyer C, Bondarenko I, Makhson A, Hartmann J, Aparicio J, Zampino M, Donea S, Ludwig H, Zubel A and Koralewski P: Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. ASCO Meeting Abstracts 25: 4035, 2007.
-
(2007)
ASCO Meeting Abstracts
, vol.25
, pp. 4035
-
-
Bokemeyer, C.1
Bondarenko, I.2
Makhson, A.3
Hartmann, J.4
Aparicio, J.5
Zampino, M.6
Donea, S.7
Ludwig, H.8
Zubel, A.9
Koralewski, P.10
-
17
-
-
34147103678
-
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
-
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon J, Van Laethem J, Maurel J, Richardson G, Wolf M and Amado R: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664, 2007.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1658-1664
-
-
Van Cutsem, E.1
Peeters, M.2
Siena, S.3
Humblet, Y.4
Hendlisz, A.5
Neyns, B.6
Canon, J.7
Van Laethem, J.8
Maurel, J.9
Richardson, G.10
Wolf, M.11
Amado, R.12
-
18
-
-
38049044037
-
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
-
Van Cutsem E, Siena S, Humblet Y, Canon J, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado R, Hogan N and Peeters M: An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 19: 92-98, 2008.
-
(2008)
Ann Oncol
, vol.19
, pp. 92-98
-
-
Van Cutsem, E.1
Siena, S.2
Humblet, Y.3
Canon, J.4
Maurel, J.5
Bajetta, E.6
Neyns, B.7
Kotasek, D.8
Santoro, A.9
Scheithauer, W.10
Spadafora, S.11
Amado, R.12
Hogan, N.13
Peeters, M.14
-
19
-
-
0345447199
-
An update on hepatic arterial infusion chemotherapy for colorectal cancer
-
Cohen A and Kemeny N: An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 8: 553-566, 2003.
-
(2003)
Oncologist
, vol.8
, pp. 553-566
-
-
Cohen, A.1
Kemeny, N.2
-
20
-
-
33947267189
-
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases
-
Zorzi D, Laurent A, Pawlik T, Lauwers G, Vauthey J and Abdalla E: Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94: 274-286, 2007.
-
(2007)
Br J Surg
, vol.94
, pp. 274-286
-
-
Zorzi, D.1
Laurent, A.2
Pawlik, T.3
Lauwers, G.4
Vauthey, J.5
Abdalla, E.6
-
21
-
-
37649015497
-
Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: The end of an era?
-
Mocellin S, Pilati P, Lise M and Nitti D: Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 25: 5649-5654, 2007.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5649-5654
-
-
Mocellin, S.1
Pilati, P.2
Lise, M.3
Nitti, D.4
-
22
-
-
0028791206
-
Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil
-
Kerr D, Ledermann J, Mcardle C, Buckels J, Neoptolemos J, Seymour M, Doughty J, Budden J and Taylor I: Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. J Clin Oncol 13: 2968-2972, 1995.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2968-2972
-
-
Kerr, D.1
Ledermann, J.2
Mcardle, C.3
Buckels, J.4
Neoptolemos, J.5
Seymour, M.6
Doughty, J.7
Budden, J.8
Taylor, I.9
-
23
-
-
0037308489
-
Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: A multicentre randomised trial
-
Kerr D, Mcardle C, Ledermann J, Taylor I, Sherlock D, Schlag PM, Buckels J, Mayer D, Cain D and Stephens R: Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361: 368-373, 2003.
-
(2003)
Lancet
, vol.361
, pp. 368-373
-
-
Kerr, D.1
Mcardle, C.2
Ledermann, J.3
Taylor, I.4
Sherlock, D.5
Schlag, P.M.6
Buckels, J.7
Mayer, D.8
Cain, D.9
Stephens, R.10
-
24
-
-
0343048340
-
Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma
-
Lorenz M and Muller H: Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 18: 243-254, 2000.
-
(2000)
J Clin Oncol
, vol.18
, pp. 243-254
-
-
Lorenz, M.1
Muller, H.2
-
25
-
-
34547663856
-
The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and ultra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: A phase II study
-
Carnaghi C, Santoro A, Rimassa L, Doci R, Rosati R, Pedicini V, Gullo G, Zuradelli M, Abbadessa G, Morenghi E, Marcon I and Garassino I: The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and ultra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study. Invest New Drugs 25: 479-485, 2007.
-
(2007)
Invest New Drugs
, vol.25
, pp. 479-485
-
-
Carnaghi, C.1
Santoro, A.2
Rimassa, L.3
Doci, R.4
Rosati, R.5
Pedicini, V.6
Gullo, G.7
Zuradelli, M.8
Abbadessa, G.9
Morenghi, E.10
Marcon, I.11
Garassino, I.12
-
26
-
-
0034994629
-
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer
-
Kern W, Beckert B, Lang N, Stemmler J, Beykirch M, Stein J, Goecke E, Waggershauser T, Braess J, Schalhorn A and Hiddemann W: Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol 12: 599-603, 2001.
-
(2001)
Ann Oncol
, vol.12
, pp. 599-603
-
-
Kern, W.1
Beckert, B.2
Lang, N.3
Stemmler, J.4
Beykirch, M.5
Stein, J.6
Goecke, E.7
Waggershauser, T.8
Braess, J.9
Schalhorn, A.10
Hiddemann, W.11
-
27
-
-
0034451952
-
Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: Role of carcino-embryonic antigen in assessment of response
-
Kern W, Beckert B, Lang N, Waggershauser T, Braess J, Schalhorn A and Hiddemann W: Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response. Anticancer Res 20: 4973-4975, 2000.
-
(2000)
Anticancer Res
, vol.20
, pp. 4973-4975
-
-
Kern, W.1
Beckert, B.2
Lang, N.3
Waggershauser, T.4
Braess, J.5
Schalhorn, A.6
Hiddemann, W.7
-
28
-
-
12444322664
-
Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer
-
Mancuso A, Giuliani R, Accettura C, Palma M, D'auria G, Cecere F, Paoluzzi L, Bezzi M, Massidda B and Cortesi E: Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res 23: 1917-1922, 2003.
-
(2003)
Anticancer Res
, vol.23
, pp. 1917-1922
-
-
Mancuso, A.1
Giuliani, R.2
Accettura, C.3
Palma, M.4
D'auria, G.5
Cecere, F.6
Paoluzzi, L.7
Bezzi, M.8
Massidda, B.9
Cortesi, E.10
-
29
-
-
32144441536
-
Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases
-
Neyns B, Van Nieuwenhove Y, Aerts M, Fontaine C, Vermeij J, Schallier D, Decoster L, De Mey J, Vandenbroucke F, Hoorens A, Delvaux G and De Greve J: Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases. Anticancer Res 26: 611-619, 2006.
-
(2006)
Anticancer Res
, vol.26
, pp. 611-619
-
-
Neyns, B.1
Van Nieuwenhove, Y.2
Aerts, M.3
Fontaine, C.4
Vermeij, J.5
Schallier, D.6
Decoster, L.7
De Mey, J.8
Vandenbroucke, F.9
Hoorens, A.10
Delvaux, G.11
De Greve, J.12
-
30
-
-
24644443860
-
Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: A trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer
-
Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob J, Boige V, Elias D, Delperro J and Luboinski M: Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23: 4881-4887, 2005.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4881-4887
-
-
Ducreux, M.1
Ychou, M.2
Laplanche, A.3
Gamelin, E.4
Lasser, P.5
Husseini, F.6
Quenet, F.7
Viret, F.8
Jacob, J.9
Boige, V.10
Elias, D.11
Delperro, J.12
Luboinski, M.13
-
31
-
-
24644484863
-
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer
-
Kemeny N, Jarnagin W, Paty P, Gonen M, Schwarte L, Morse M, Leonard G, D'angelica M, Dematteo R, Blumgart L and Fong Y: Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23: 4888-4896, 2005.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4888-4896
-
-
Kemeny, N.1
Jarnagin, W.2
Paty, P.3
Gonen, M.4
Schwarte, L.5
Morse, M.6
Leonard, G.7
D'angelica, M.8
Dematteo, R.9
Blumgart, L.10
Fong, Y.11
-
32
-
-
38049164083
-
Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure
-
Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, Dromain C, Pocard M and Ducreux M: Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 15: 219-226, 2008.
-
(2008)
Ann Surg Oncol
, vol.15
, pp. 219-226
-
-
Boige, V.1
Malka, D.2
Elias, D.3
Castaing, M.4
De Baere, T.5
Goere, D.6
Dromain, C.7
Pocard, M.8
Ducreux, M.9
-
33
-
-
37349026722
-
Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: A retrospective analysis
-
Gallagher D, Capanu M, Raggio G and Kemeny N: Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol 18: 1995-1999, 2007.
-
(2007)
Ann Oncol
, vol.18
, pp. 1995-1999
-
-
Gallagher, D.1
Capanu, M.2
Raggio, G.3
Kemeny, N.4
-
34
-
-
33947705790
-
Techniques for the placement of hepatic artery catheters for regional chemotherapy in unresectable liver metastases
-
Van Nieuwenhove Y, Aerts M, Neyns B and Delvaux G: Techniques for the placement of hepatic artery catheters for regional chemotherapy in unresectable liver metastases. Eur J Surg Oncol 33: 336-340, 2007.
-
(2007)
Eur J Surg Oncol
, vol.33
, pp. 336-340
-
-
Van Nieuwenhove, Y.1
Aerts, M.2
Neyns, B.3
Delvaux, G.4
-
35
-
-
34249670190
-
Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: A Phase II-study and historical comparison with the surgical approach
-
Hildebrandt B, Pech M, Nicolaou A, Langrehr J, Kurcz J, Bartels B, Miersch A, Felix R, Neuhaus P, Riess H, Dorken B and Ricke J: Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a Phase II-study and historical comparison with the surgical approach. BMC Cancer 7: 69, 2007.
-
(2007)
BMC Cancer
, vol.7
, pp. 69
-
-
Hildebrandt, B.1
Pech, M.2
Nicolaou, A.3
Langrehr, J.4
Kurcz, J.5
Bartels, B.6
Miersch, A.7
Felix, R.8
Neuhaus, P.9
Riess, H.10
Dorken, B.11
Ricke, J.12
-
36
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck Smeetingg, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom A, Christian M and Gwyther S: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Smeetingg, A.2
Eisenhauer, E.3
Wanders, J.4
Kaplan, R.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.9
Christian, M.10
Gwyther, S.11
-
37
-
-
33748460684
-
Complete response of colorectal liver metastases after chemotherapy: Does it mean cure?
-
Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, Mitry E, Rougier P and Nordlinger B: Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24: 3939-3945, 2006.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3939-3945
-
-
Benoist, S.1
Brouquet, A.2
Penna, C.3
Julie, C.4
El Hajjam, M.5
Chagnon, S.6
Mitry, E.7
Rougier, P.8
Nordlinger, B.9
-
38
-
-
40149088765
-
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
-
De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E and Tejpar S: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515, 2008.
-
(2008)
Ann Oncol
, vol.19
, pp. 508-515
-
-
De Roock, W.1
Piessevaux, H.2
De Schutter, J.3
Janssens, M.4
De Hertogh, G.5
Personeni, N.6
Biesmans, B.7
Van Laethem, J.L.8
Peeters, M.9
Humblet, Y.10
Van Cutsem, E.11
Tejpar, S.12
-
39
-
-
38649099966
-
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
-
Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Bue E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold M, Rougier P, Ducreux M, Tomasic G, Emile J, Penault-Llorca F and Laurent-Puig P: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008.
-
(2008)
J Clin Oncol
, vol.26
, pp. 374-379
-
-
Lievre, A.1
Bachet, J.B.2
Boige, V.3
Cayre, A.4
Le Corre, D.5
Bue, E.6
Ychou, M.7
Bouche, O.8
Landi, B.9
Louvet, C.10
Andre, T.11
Bibeau, F.12
Diebold, M.13
Rougier, P.14
Ducreux, M.15
Tomasic, G.16
Emile, J.17
Penault-Llorca, F.18
Laurent-Puig, P.19
-
40
-
-
35348908314
-
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
-
Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne L, Cavalli F and Mazzucchelli L: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145, 2007.
-
(2007)
Br J Cancer
, vol.97
, pp. 1139-1145
-
-
Frattini, M.1
Saletti, P.2
Romagnani, E.3
Martin, V.4
Molinari, F.5
Ghisletta, M.6
Camponovo, A.7
Etienne, L.8
Cavalli, F.9
Mazzucchelli, L.10
-
41
-
-
34247278727
-
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy
-
Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Calais M, Bastit L, Killian A, Sesboue R, Tuech J, Queuniet A, Paillot B, Sabourin J, Michot F, Michel P and Frebourg T: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169, 2007.
-
(2007)
Br J Cancer
, vol.96
, pp. 1166-1169
-
-
Di Fiore, F.1
Blanchard, F.2
Charbonnier, F.3
Le Pessot, F.4
Lamy, A.5
Calais, M.6
Bastit, L.7
Killian, A.8
Sesboue, R.9
Tuech, J.10
Queuniet, A.11
Paillot, B.12
Sabourin, J.13
Michot, F.14
Michel, P.15
Frebourg, T.16
-
42
-
-
17844362179
-
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study
-
Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S and Bardelli A: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-286, 2005.
-
(2005)
Lancet Oncol
, vol.6
, pp. 279-286
-
-
Moroni, M.1
Veronese, S.2
Benvenuti, S.3
Marrapese, G.4
Sartore-Bianchi, A.5
Di Nicolantonio, F.6
Gambacorta, M.7
Siena, S.8
Bardelli, A.9
|